The other striated muscle: The role of sarcopenia in older persons with heart failure

Reeves, Gordon R.; Pandey, Ambarish; Kitzman, Dalane W.

doi:10.1111/jgs.17160

Cited by 5 publications

(3 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…De acordo com uma meta-análise recente, a prevalência combinada da sarcopenia na IC foi de 34%, 4 mas ela pode chegar a 50% entre pacientes hospitalizados por piora da IC. 5 Ela também está associada a um prognóstico desfavorável, 3 contribuindo para a redução da capacidade de exercício, 6 mortalidade global e cardiovascular mais alta, e aumento das repetições da hospitalização, bem como a perda da autonomia e uma qualidade de vida pior. 3 , 4 …”

Section: Introductionunclassified

“…According to a recent meta-analysis, the pooled prevalence of sarcopenia in HF was 34%, 4 but it can be as high as 50% among patients admitted to worsening HF. 5 It is also associated with an unfavorable prognosis, 3 contributing to reduced exercise capacity, 6 higher cardiovascular and all-cause mortality, and increased hospital readmissions, as well as the loss of autonomy and a lower quality of life. 3 , 4 …”

Section: Introductionmentioning

confidence: 99%

“…De acordo com uma metaanálise recente, a prevalência combinada da sarcopenia na IC foi de 34%, 4 mas ela pode chegar a 50% entre pacientes hospitalizados por piora da IC. 5 Ela também está associada a um prognóstico desfavorável, 3 contribuindo para a redução da capacidade de exercício, 6 mortalidade global e cardiovascular mais alta, e aumento das repetições da hospitalização, bem como a perda da autonomia e uma qualidade de vida pior. 3,4 A etiologia da sarcopenia é complexa e multifatorial, 7 incluindo anormalidades endócrinas e metabólica, e tem interações próximas com a inflamação sistêmica de baixo grau em indivíduos idosos (inflammageing), 7,8 redução da síntese e da regeneração da proteína, aumento da apoptose e lise de proteína.…”

Section: Introductionunclassified

See 2 more Smart Citations

Sarcopenia: Marcadores Inflamatórios e Humorais em Pacientes Idosos com Insuficiência Cardíaca

Sangali¹,

Souza²,

Ribeiro³

et al. 2023

Arquivos Brasileiros De Cardiologia

View full text Add to dashboard Cite

Resumo Fundamento Sarcopenia é altamente prevalente em pacientes com insuficiência cardíaca (IC), e o envolvimento de biomarcadores em sua fisiopatologia é sugerido, mas poucos estudos foram realizados em relação a pacientes sarcopênicos com IC. Objetivos Avaliar a associação entre marcadores inflamatórios e humorais e sarcopenia, bem como o impacto da sarcopenia na qualidade de vida e na capacidade funcional em pacientes mais velhos com IC. Métodos Neste estudo transversal, 90 pacientes ambulatoriais com IC, com idade ≥60 anos, foram avaliados quanto a sarcopenia (critérios diagnósticos EWGSOP2), inflamação (Proteína C reativa de alta sensibilidade [PCR-as], Interleucina-6 [IL-6], fator de necrose tumoral alfa [TNF-α]) e marcadores humorais (testosterona total e fator de crescimento semelhante à insulina tipo 1 [IGF-1]), atividade física (Questionário internacional de atividade física), qualidade de vida ( Minnesota Living with Heart Failure Questionnaire – Questionário Minnesota sobre conviver com a insuficiência cardíaca), e capacidade funcional (teste de caminhada de 6 minutos). O nível de significância estatística adotado foi p <0,05. Resultados Os pacientes tinham uma média de idade de 69,4 ± 7,2 anos, 67,8% eram do sexo masculino, com fração de ejeção ventricular esquerda (FEVE) de 35,9 ± 11,9% e 22 (24,4%) eram sarcopênicos. Idade (73,1 ± 8,1 e 68,3 ± 6,5 anos; p= 0,006), índice de massa corporal (IMC) (23,1 ± 2,8 e 28,2 ± 4,2 kg/m 2 ; p <0,001), e FEVE (29,9 ± 8,8 e 37,9 ± 12,1%; p= 0,005) eram diferentes nos grupos com e sem sarcopenia, respectivamente. Depois de normalizar em relação à idade, etnia, IMC, FEVE, e o uso de inibidores da enzima conversora de angiotensina/bloqueadores de receptor de angiotensina, a sarcopenia foi associada a níveis séricos de IL-6 mais altos e capacidade funcional pior. Conclusão Em pacientes com IC, a sarcopenia foi associada aos níveis de IL-6 e à capacidade funcional.

show abstract

Section: Introductionunclassified

Section: Introductionmentioning

confidence: 99%

Section: Introductionunclassified

See 1 more Smart Citation

Sarcopenia: Marcadores Inflamatórios e Humorais em Pacientes Idosos com Insuficiência Cardíaca

Sangali¹,

Souza²,

Ribeiro³

et al. 2023

Arquivos Brasileiros De Cardiologia

View full text Add to dashboard Cite

show abstract

A novel controlled metabolic accelerator for the treatment of obesity‐related heart failure with preserved ejection fraction: Rationale and design of the Phase 2a HuMAIN trial

Kitzman,

Lewis,

Pandey

et al. 2024

European J of Heart Fail

View full text Add to dashboard Cite

AimsCompared with those without obesity, patients with obesity‐related heart failure with preserved ejection fraction (HFpEF) have worse symptoms, haemodynamics, and outcomes. Current weight loss strategies (diet, drug, and surgical) work through decreased energy intake rather than increased expenditure and cause significant loss of skeletal muscle mass in addition to adipose tissue. This may have adverse implications for patients with HFpEF, who already have reduced skeletal muscle mass and function and high rates of physical frailty. Mitochondrial uncoupling agents may have unique beneficial effects by producing weight loss via increased catabolism rather than reduced caloric intake, thereby causing loss of adipose tissue while sparing skeletal muscle. HU6 is a controlled metabolic accelerator that is metabolized to the mitochondrial uncoupling agent 2,4‐dinotrophenol. HU6 selectively increases carbon oxidation from fat and glucose while also decreasing toxic reactive oxygen species (ROS) production. In addition to sparing skeletal muscle loss, HU6 may have other benefits relevant to obesity‐related HFpEF, including reduced specific tissue depots contributing to HFpEF; improved glucose utilization; and reduction in systemic inflammation via both decreased ROS production from mitochondria and decreased cytokine elaboration from excess, dysfunctional adipose.MethodsWe describe the rationale and design of HuMAIN‐HFpEF, a Phase 2a randomized, double‐blind, placebo‐controlled, dose‐titration, parallel‐group trial in patients with obesity‐related HFpEF to evaluate the effects of HU6 on weight loss, body composition, exercise capacity, cardiac structure and function, metabolism, and inflammation, and identify optimal dosage for future Phase 3 trials.ConclusionsHuMAIN will test a promising novel agent for obesity‐related HFpEF.

show abstract

Sarcopenia is linked to higher levels of B-type natriuretic peptide and its N-terminal fragment in heart failure: a systematic review and meta-analysis

Prokopidis,

Morwani-Mangnani,

McDowell

et al. 2024

Eur Geriatr Med

View full text Add to dashboard Cite

Aims Sarcopenia is linked to impaired physical function and exercise tolerance. The aim of this systematic review and meta-analysis was to examine the association of sarcopenia and low appendicular skeletal muscle (ASM) with biomarkers of cardiac function, B-type natriuretic peptide (BNP) and its N-terminal fragment (NT-proBNP), in patients with heart failure (HF). Methods and results From inception until May 2023, a systematic literature search of observational studies was undertaken utilizing the PubMed, Web of Science, Scopus, and Cochrane Library databases. A meta-analysis employing a random-effects model was used to compute the pooled effects (CRD42023418465). Overall, 16 studies were included in this systematic review and meta-analysis. Our main analysis showed that sarcopenia in HF was linked to significantly higher levels of BNP (MD: 87.76, 95% CI 20.74–154.78, I2 = 61%, P = 0.01) and NT-proBNP (MD: 947.45, 95% CI 98.97–1795.93, I2 = 35%, P = 0.03). Similarly, low ASM was associated with significantly higher levels of BNP (MD: 118.95, 95% CI 46.91–191.00, I2 = 93%, P < 0.01) and NT-proBNP (MD: 672.01, 95% CI 383.72–960.30, I2 = 2%, P < 0.01). The quality of the included cohort studies was considered moderate, using the binary AXIS checklist and the Cochrane Tool to Assess the Risk of Bias in Cohort Studies. Conclusions In patients with HF, sarcopenia and reduced ASM are associated with considerably higher plasma levels of BNP and NT-proBNP. Future research is required to investigate whether sarcopenia may express dysregulated biomarkers of cardiac function. Graphical abstract

show abstract

The other striated muscle: The role of sarcopenia in older persons with heart failure

Abstract: This editorial comments on the article by https://onlinelibrary.wiley.com/doi/10.1111/jgs.17108. in this issue.

Cited by 5 publications

References 22 publications

Sarcopenia: Marcadores Inflamatórios e Humorais em Pacientes Idosos com Insuficiência Cardíaca

Sarcopenia: Marcadores Inflamatórios e Humorais em Pacientes Idosos com Insuficiência Cardíaca

A novel controlled metabolic accelerator for the treatment of obesity‐related heart failure with preserved ejection fraction: Rationale and design of the Phase 2a HuMAIN trial

Sarcopenia is linked to higher levels of B-type natriuretic peptide and its N-terminal fragment in heart failure: a systematic review and meta-analysis

Contact Info

Product

Resources

About